Clinical Trial Update: An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 randomized, double-blind trial comparing BCD-132 to teriflunomide for multiple sclerosis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• BCD-132 (BCD-132)
• Teriflunomide (teriflunomide)

Snippet

Sponsor: Biocad | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED